The FDA has approved Mylan Laboratories Nebivolol for high blood pressure contingent on Mylan's submission of preclinical data and the resolution of labeling requirements. The approvable letter comes slightly more than a year after the drug company filed its NDA. Mylan representatives say the data from an ongoing preclinical study of the beta blocker should satisfy the agency. Mylan licensed Nebivolol from Janssen Pharmaceutica four years ago.
- read this story from MSN for more on the approval
ALSO: Carl Icahn has dropped his lawsuit against Richard Perry, who had supported Mylan's failed bid to buy King Pharmaceuticals. Article